STOCK TITAN

Cue Health Inc. - HLTH STOCK NEWS

Welcome to our dedicated page for Cue Health news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Cue Health stock.

Cue Health Inc. (HLTH) is a pioneering healthcare technology company that empowers individuals to manage their health with precision and convenience. Cue Health offers a revolutionary device that tracks key health and lifestyle indicators at the molecular level, including inflammation, vitamin D, fertility, influenza, and testosterone. This compact, user-friendly device enables consumers to perform these tests at home in just minutes.

The data collected by Cue is sent via Bluetooth 4.0 to the user’s smartphone, where the free Cue app provides an in-depth analysis of how activity, food, and sleep impact their health. By using noninvasive samples such as saliva, blood, or nasal swabs, users can access lab-quality information about their bodies on demand.

Recent Achievements:

  • The company has gained recognition for its innovative approach to personal health monitoring, making previously lab-exclusive data accessible to the general public.
  • Partnerships with leading healthcare providers have expanded the usability and integration of Cue devices.

Current Projects:

  • Continued development of advanced features within the Cue app, including interactive charts that help users visualize their health trends.
  • Research-based recommendations for foods proven to support optimal health tailored to the user's specific molecular data.

By offering a comprehensive tool for health management, Cue Health Inc. continues to play a significant role in transforming how individuals monitor and improve their well-being. The company’s dedication to providing accessible and real-time health data is a testament to its commitment to innovation and public health.

Rhea-AI Summary

Cue Health (Nasdaq: HLTH), a healthcare technology company, has filed for Chapter 7 bankruptcy in the District of Delaware, aiming to wind down its business. Despite efforts to reduce costs and find additional financing or strategic transactions, the Board of Directors, after thorough review and consultation, determined that filing for Chapter 7 was in the best interest of stakeholders. A bankruptcy trustee will be appointed to manage the liquidation of assets to pay creditors. Cue Health expressed gratitude to its employees, customers, and vendors for their contributions and partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.51%
Tags
none
-
Rhea-AI Summary

Cue Health (Nasdaq: HLTH) has received a warning letter from the FDA regarding its Emergency Use Authorized (EUA) COVID-19 test. The healthcare technology company is currently evaluating the letter and determining an appropriate response. Further details will be provided in the coming days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.94%
Tags
-
Rhea-AI Summary

Cue Health Inc. (HLTH) is set to release its first quarter 2024 financial results on May 13, 2024, without hosting a conference call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.85%
Tags
Rhea-AI Summary
Cue Health Inc. (HLTH) appoints Clint Sever as CEO and adds Dr. Paul Brown and Dr. Lisa Danzig as strategic advisors to enhance business operations and commercialization efforts. The company aims to review its business strategy and cost structure for future growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
Rhea-AI Summary
Cue Health Inc. reports $18.8 million in Q4 revenue and $70.9 million in full-year 2023 revenue. The company submitted clinical data for RSV and Flu A/B tests to the FDA. Cue is in late-stage development of Herpes + Mpox Multiplex Molecular Test. They executed cost reduction plans saving $200 million annually. Fourth quarter revenue breakdown shows private sector revenue at $17.0 million and public sector revenue at $1.8 million. Cue reported a GAAP net loss of $148.4 million in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.14%
Tags
-
Rhea-AI Summary
Cue Health Inc. (HLTH) will announce its Q4 and full-year 2023 financial results on March 13, 2024. The company will host a conference call and webcast to discuss the results and recent highlights. Participants can register in advance for the call and access it via telephone or webinar.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.9%
Tags
Rhea-AI Summary
Cue Health (HLTH) partners with Tarsadia Investments and appoints Rishi Reddy to its Board of Directors. The company aims to enhance shareholder value and improve operational efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
management
-
Rhea-AI Summary
Cue Health, a healthcare technology company (Nasdaq: HLTH), will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
conferences
-
Rhea-AI Summary
HLTH - Cue Health Inc. Reports Impressive Q3 2023 Financial Results, Revenue Exceeds Expectations, Plans for New Multiplex Molecular Test Development, and Achieves Cost Savings. Revenue of $17.5 million, 50% above guidance range. Three tests in review with the FDA. Annualized run rate cost savings of approximately $165 million. Net change in cash for the quarter was $(17.1) million. Ended the third quarter with cash and cash equivalents of $111.5 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
Rhea-AI Summary
Cue Health Inc. will release its Q3 2023 financial results on November 8, 2023. A conference call and webcast will be held to discuss the results and recent highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags

FAQ

What is the current stock price of Cue Health (HLTH)?

The current stock price of Cue Health (HLTH) is $0.0434 as of June 5, 2024.

What is the market cap of Cue Health (HLTH)?

The market cap of Cue Health (HLTH) is approximately 6.9M.

What does Cue Health Inc. specialize in?

Cue Health Inc. specializes in providing a device that tracks key health and lifestyle indicators at the molecular level, enabling at-home testing and real-time health data analysis.

How does Cue's device work?

The device uses noninvasive samples such as saliva, blood, or nasal swabs to measure health indicators and sends the data via Bluetooth to the user’s smartphone for analysis.

What health indicators can Cue track?

Cue can track inflammation, vitamin D, fertility, influenza, and testosterone levels in just minutes at home.

What is the Cue app?

The Cue app is a free application that receives data from the Cue device and provides detailed insights into how activity, food, and sleep affect your health.

What recent achievements has Cue Health made?

Cue Health has been recognized for making lab-quality health data accessible at home and has formed partnerships with leading healthcare providers to enhance device usability.

What are some current projects at Cue Health?

Current projects include developing advanced app features like interactive health charts and offering personalized, research-based health recommendations.

How does Cue Health send data to a user's smartphone?

Cue Health uses Bluetooth 4.0 technology to send health data from the device to the user's smartphone.

Can the Cue device track trends in personal health?

Yes, the Cue app provides interactive charts that allow users to monitor their health trends over time and discover new patterns.

Is Cue Health's testing method invasive?

No, Cue Health uses noninvasive methods such as saliva, blood, or nasal swabs to collect health data.

What makes Cue Health unique?

Cue Health is unique in its ability to provide immediate, lab-quality health data at home, enabling users to make informed health decisions in real-time.

Cue Health Inc.

Nasdaq:HLTH

HLTH Rankings

HLTH Stock Data

6.90M
159.09M
11.57%
52.81%
0.49%
Health Information Services
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO